TARS
Tarsus Pharmaceuticals, Inc.78.28
-2.20-2.73%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Key Stats
Market Cap
3.32BP/E (TTM)
-Basic EPS (TTM)
-1.99Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Tarsus Pharmaceuticals crushed Q3 with XDEMVY net product sales rocketing 147% y/y to $118.7M, while narrowing operating loss to $14.5M from $25.2M and net loss to $12.6M ($0.30/share) from $23.4M ($0.61/share)—EPS reconciles to 42.6M diluted shares. YTD sales hit $299.7M, up from $113.7M, yet SG&A swelled to support the ramp. Cash swelled to $112.7M plus $289.1M marketable securities, backed by $72.3M net debt under the 2024 Credit Facility (SOFR+6.75%, due 2029). Revenue relies on two customers for 77%. XDEMVY sales keep surging.
8-K
XDEMVY sales hit $118.7M
Tarsus Pharmaceuticals blasted Q3 XDEMVY net sales to $118.7 million, up 147% from $48.1 million last year, fueled by over 103,000 bottles delivered versus 41,400 prior. Weekly multi-patient prescribers surged 30% quarter-over-quarter. XDEMVY sales exploded. Yet net loss narrowed to $12.6 million from $23.4 million, with cash at $401.8 million; pipeline advances TP-04 for ocular rosacea Phase 2 in December.
8-K
Record $102.7M XDEMVY sales
Tarsus Pharmaceuticals reported record Q2 2025 net product sales of $102.7 million for XDEMVY, up 152% from $40.8 million in 2024, fueled by 91,000 bottles distributed and a DTC campaign that tripled consumer awareness while expanding prescribers by over 30% to more than 20,000. Pipeline progress includes planned Phase 2 starts for TP-04 in ocular rosacea by H2 2025 and TP-05 for Lyme prevention in 2026, with global regulatory meetings on track. Yet net loss narrowed to $20.3 million from $33.3 million. XDEMVY solidifies as Demodex blepharitis standard.
10-Q
Q2 FY2025 results
Tarsus Pharmaceuticals posted strong Q2 FY2025 results, with net product sales from XDEMVY surging 152% year-over-year to $102.7 million, while six-month sales climbed 176% to $181.0 million; yet operating losses narrowed to $22.2 million from $33.3 million a year earlier, thanks to revenue momentum outpacing expense growth. Gross margins held steady around 94%, supported by efficient scaling, though selling, general, and administrative costs rose with marketing push. Diluted EPS improved to $(0.48) from $(0.88), aligning with 42.4 million weighted shares and no anti-dilution effects. Cash swelled to $381.1 million, bolstered by a $134.8 million March offering, against $72.1 million in long-term debt under the 2024 Credit Facility maturing April 2029. XDEMVY now reaches over 90% reimbursement coverage. Still, heavy reliance on a single product leaves room for commercialization hiccups.
8-K
Tarsus annual meeting results
Tarsus Pharmaceuticals held its annual stockholder meeting on June 12, 2025, where shareholders elected Bobak Azamian and Katherine Goodrich as Class II directors until 2028, despite some withheld votes on Azamian. They approved executive compensation on a non-binding basis and opted for annual say-on-pay votes, while ratifying Ernst & Young as auditors for 2025. Strong turnout signals board stability. No major disruptions noted.
CLSD
Clearside Biomedical, Inc.
0.41+0.41
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
LIANY
LianBio
0.09+0.00
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05